When.com Web Search

  1. Ads

    related to: lipitor pfizer astellas generic

Search results

  1. Results From The WOW.Com Content Network
  2. Pfizer agrees to pay $93 million to settle Lipitor antitrust ...

    www.aol.com/news/pfizer-agrees-pay-93-million...

    Pfizer introduced Lipitor in 1997, and the drug drove more than $130 billion in sales during its first 14 years on the market. The pharma distributors claimed Pfizer fraudulently sought to extend ...

  3. Lipitor? What Was That Again? - AOL

    www.aol.com/news/2012-07-31-lipitor-what-was...

    Pfizer (NYS: PFE) used to sell Lipitor exclusively in the United States. And it was a huge component of the company's revenue and earnings. Honest. I swear. You certainly wouldn't know it from the ...

  4. Pfizer Sues Merck to Block Lipitor/Zetia Combo Pill - AOL

    www.aol.com/2011/10/13/pfizer-sues-merck-to...

    But this time it's Pfizer (NYS: PFE) and Merck (NYS: Usually, it's a branded drugmaker fighting off a generics challenge from a copycat drugmaker. Pfizer Sues Merck to Block Lipitor/Zetia Combo Pill

  5. 3 Things More Important to Pfizer Than Losing Lipitor - AOL

    www.aol.com/news/2011-11-30-3-things-more...

    L-Day is upon us. That thud you just heard was billions of dollars of Lipitor sales heading over the patent cliff. Pfizer (NYS: PFE) no longer has exclusivity on the drug as of today. We've known ...

  6. Apotex - Wikipedia

    en.wikipedia.org/wiki/Apotex

    In 2010, Apotex launched a generic version of Pfizer Inc.'s cholesterol-lowering Lipitor drug in Canada, after four years of patent litigation with Pfizer. Apotex's generic version was launched under the name of Apo-Atorvastatin. [17] This saved provincial health programs over $800 million per year.

  7. Torcetrapib - Wikipedia

    en.wikipedia.org/wiki/Torcetrapib

    Torcetrapib (CP-529,414, Pfizer) was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.Its development was halted in 2006 when phase III studies showed excessive all-cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib.